

410-9 PCT Seq final
SEQUENCE LISTING

<110> BionTech AG, Johannes Gutenberg-Universität Mainz
 <120> Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen
 bei RNA-Immunisierung
 <130> 410-9 PCT
 <150> DE 10 2008 061 522.6
 <151> 2008-12-10
 <160> 6
 <170> PatentIn version 3.3
 <210> 1
 <211> 235
 <212> PRT
 <213> Homo sapiens
 <400> 1

Met Thr Val Leu Ala Pro Ala Trp Ser Pro Thr Thr Tyr Leu Leu Leu
 1 5 10 15

Leu Leu Leu Leu Ser Ser Gly Leu Ser Gly Thr Gln Asp Cys Ser Phe
 20 25 30

Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu
 35 40 45

Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu
 50 55 60

Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
 65 70 75 80

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
 85 90 95

Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
 100 105 110

Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
 115 120 125

Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
 130 135 140

Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
 145 150 155 160

Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Glu Ala
 165 170 175

Thr Ala Pro Thr Ala Pro Gln Pro Pro Leu Leu Leu Leu Leu Leu Leu
 Seite 1

410-9 PCT Seq final
185

180

190

Pro Val Gly Leu Leu Leu Leu Ala Ala Ala Trp Cys Leu His Trp Gln
195 200 205

Arg Thr Arg Arg Arg Thr Pro Arg Pro Gly Glu Gln Val Pro Pro Val
210 215 220

Pro Ser Pro Gln Asp Leu Leu Leu Val Glu His
225 230 235

<210> 2
<211> 232
<212> PRT
<213> Mus musculus
<400> 2

Met Thr Val Leu Ala Pro Ala Trp Ser Pro Asn Ser Ser Leu Leu Leu
1 5 10 15

Leu Leu Leu Leu Leu Ser Pro Cys Leu Arg Gly Thr Pro Asp Cys Tyr
20 25 30

Phe Ser His Ser Pro Ile Ser Ser Asn Phe Lys Val Lys Phe Arg Glu
35 40 45

Leu Thr Asp His Leu Leu Lys Asp Tyr Pro Val Thr Val Ala Val Asn
50 55 60

Leu Gln Asp Glu Lys His Cys Lys Ala Leu Trp Ser Leu Phe Leu Ala
65 70 75 80

Gln Arg Trp Ile Glu Gln Leu Lys Thr Val Ala Gly Ser Lys Met Gln
85 90 95

Thr Leu Leu Glu Asp Val Asn Thr Glu Ile His Phe Val Thr Ser Cys
100 105 110

Thr Phe Gln Pro Leu Pro Glu Cys Leu Arg Phe Val Gln Thr Asn Ile
115 120 125

Ser His Leu Leu Lys Asp Thr Cys Thr Gln Leu Leu Gly Leu Lys Pro
130 135 140

Cys Ile Gly Lys Ala Cys Gln Asn Phe Ser Arg Cys Leu Glu Val Gln
145 150 155 160

Cys Gln Pro Asp Ser Ser Thr Leu Leu Pro Pro Arg Ser Pro Ile Ala
165 170 175

Leu Glu Ala Thr Glu Leu Pro Glu Pro Arg Pro Arg Gln Leu Leu Leu
180 185 190

410-9 PCT Seq final

Leu Leu Leu Leu Leu Leu Pro Leu Thr Leu Val Leu Leu Ala Ala Ala
195 200 205

Trp Gly Leu Arg Trp Gln Arg Ala Arg Arg Arg Gly Glu Leu His Pro
210 215 220

Gly Val Pro Leu Pro Ser His Pro
225 230

<210> 3
<211> 1056
<212> DNA
<213> Homo sapiens

<400> 3
tctctggctg tcacccggct tggccccttc cacacccaac tggggcaagc ctgacccggc 60
gacaggaggc atgagggggc cccggccgaa atgacagtgc tggcgccagc ctggagccca 120
acaacctatc tcctcctgct gctgctgctg agctcgggac tcagtgggac ccaggactgc 180
tccttccaac acagcccat ctcctccgac ttcgctgtca aaatccgtga gctgtctgac 240
tacctgcttc aagattaccc agtcaccgtg gcctccaacc tgcaggacga ggagctctgc 300
gggggcctct ggcggctggt cctggcacag cgctggatgg agcggctcaa gactgtcgct 360
gggtccaaga tgcaaggctt gctggagcgc gtgaacacgg agatacactt tgtcacaaaa 420
tgtgcctttc agccccccc cagctgtctt cgcttcgtcc agaccaacat ctccgcctc 480
ctgcaggaga cctccgagca gctggtggcg ctgaagccct ggatcactcg ccagaacttc 540
tcccggtgcc tggagctgca gtgtcagccc gactcctcaa ccctgccacc cccatggagt 600
ccccggcccc tggaggccac agccccgaca gccccgcagc cccctctgct cctcctactg 660
ctgctgcccc tgggcctcct gctgctggcc gctgcctggt gcctgcactg gcagaggacg 720
cggcggagga caccgccc tggggagcag gtgcccccg tccccagtcc ccaggacctg 780
ctgcttgctg agcactgacc tggccaaggc ctcatcctgg ggaggatact gaggcacaca 840
gaggggagtc accagccaga ggatgcatag cctggacaca gaggaagttg gctagaggcc 900
ggtcccttcc ttggggccct ctcatccct cccagaatg gaggcaacgc cagaatccag 960
caccggcccc atttacccaa ctctgtacaa agcccttgct cccatgaaat tgtatataaa 1020
tcaccccttt ctacaaaaaa aaaaaaaaaa aaaaaa 1056

<210> 4
<211> 1152
<212> DNA
<213> Mus musculus

<400> 4
gaattcgcgg ccgcgtcgac attctgggga cgctcggtcgg ggttcttaga agaggagatg 60
acttttcaca gtcactgagg ctctgtcagg aagcctgggg gagcaggagg cggaaaccga 120
cccacatcaa gggcggcagg gccgggcggc ggggtacagg gggtgggggg gaaggggctg 180

410-9 PCT Seq final

cagggtatga gcccgagacc tgccctcctg tcacttccaa gaacctgtca caggcatgag 240
 ggggtccccg cagagatgac agtgctggcg ccagcctgga gcccaaattc ctccctgttg 300
 ctgctgttgc tgctgctgag tccttgccctg cgggggacac ctgactgtta cttcagccac 360
 agtcccatct cctccaactt caaagtgaag tttagagagt tgactgacca cctgcttaaa 420
 gattaccag tcactgtggc cgtcaatctt caggacgaga agcactgcaa ggccttgagg 480
 agcctcttcc tagcccagcg ctggatagag caactgaaga ctgtggcagg gtctaagatg 540
 caaacgcttc tggaggacgt caacaccgag atacattttg tcacctcatg taccttccag 600
 cccctaccag aatgtctgcg attcgtccag accaaccatct cccacctcct gaaggacacc 660
 tgcacacagc tgcttggtct gaagccctgt atcgggaagg cctgccagaa tttctctcgg 720
 tgcctggagg tgcagtgcc gccggactcc tccacctgc tgcaccaag gaggccata 780
 gccctagaag ccacggagct cccagagcct cggcccaggc agctgttgct cctgctgctg 840
 ctgctgctgc ctctcacact ggtgctgctg gcagccgcct ggggacctcg ctggcaaagg 900
 gcaagaagga ggggggagct ccacctggg gtgccccctc cctcccatcc ctaggatgag 960
 agccttgctgc atcgttgact cagccagggt cttatctcga tgaggctctca atatgttgcc 1020
 caaactgact ttgaaaacct cgatgcacct tcctgcccc caaacttcca aacagctggg 1080
 cttacgggca tgctatatac aacaaggctt tcttttcttc tttcttggtg ctagagttgg 1140
 gaaccaaacc aa 1152

<210> 5
 <211> 224
 <212> PRT
 <213> Homo sapiens

<400> 5

Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser
 1 5 10 15

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
 20 25 30

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro
 35 40 45

Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
 50 55 60

Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val
 65 70 75 80

Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
 85 90 95

Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr
 Seite 4

410-9 PCT Seq final

100

105

110

Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125

Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
130 135 140

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160

Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser
180 185 190

Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
210 215 220

<210> 6
<211> 411
<212> PRT
<213> Artificial

<220>
<223> Fusionsprotein

<400> 6

Met Thr Val Leu Ala Pro Ala Trp Ser Pro Thr Thr Tyr Leu Leu Leu
1 5 10 15

Leu Leu Leu Leu Ser Ser Gly Leu Ser Gly Thr Gln Asp Cys Ser Phe
20 25 30

Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu
35 40 45

Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu
50 55 60

Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
65 70 75 80

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
85 90 95

Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
100 105 110

410-9 PCT Seq final

Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
 115 120 125
 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
 130 135 140
 Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
 145 150 155 160
 Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Glu Ala
 165 170 175
 Thr Ala Pro Thr Ala Pro Gln Pro Pro Arg Ser Pro Pro Cys Pro Ser
 180 185 190
 Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
 195 200 205
 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
 210 215 220
 Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn
 225 230 235 240
 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
 245 250 255
 Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
 260 265 270
 Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
 275 280 285
 Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys
 290 295 300
 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu
 305 310 315 320
 Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
 325 330 335
 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
 340 345 350
 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
 355 360 365
 Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly
 370 375 380

410-9 PCT Seq final

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
385 390 395 400

Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
405 410